These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32247206)

  • 41. Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial.
    Macias VA; Barrera-Mellado I
    BJU Int; 2020 Feb; 125(2):215-225. PubMed ID: 31614071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity.
    Ippolito E; Mantini G; Morganti AG; Mazzeo E; Padula GD; Digesù C; Cilla S; Frascino V; Luzi S; Massaccesi M; Macchia G; Deodato F; Mattiucci GC; Piermattei A; Cellini N
    Am J Clin Oncol; 2012 Apr; 35(2):158-62. PubMed ID: 21336090
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
    Sanmamed N; Lee J; Berlin A; Craig T; Lao B; Rink A; Bayley A; Catton C; Sundaramurthy A; Foltz W; McPartlin A; Ghai S; Astenafu E; Gospodarowicz M; Warde P; Ménard C; Chung P
    Radiother Oncol; 2020 Aug; 149():240-245. PubMed ID: 32447033
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
    Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
    Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.
    Thor M; Deasy JO; Paulus R; Robert Lee W; Amin MB; Bruner DW; Low DA; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Gore EM; Albert M; Pisansky TM; Faria SL; Chen Y; Koontz BF; Swanson GP; Pugh SL; Sandler HM
    Radiother Oncol; 2019 Jun; 135():19-24. PubMed ID: 31015166
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
    Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
    Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extreme hypofractionated proton radiotherapy for prostate cancer using pencil beam scanning: Dosimetry, acute toxicity and preliminary results.
    Kubeš J; Vondráček V; Andrlik M; Navrátil M; Sláviková S; Vítek P; Rosina J; Abrahámová J; Prausová J; Grebenyuk A; Dědečková K
    J Med Imaging Radiat Oncol; 2019 Dec; 63(6):829-835. PubMed ID: 31486267
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience.
    Hegazy MW; Mahmood RI; Al Otaibi MF; Khalil EM
    J Egypt Natl Canc Inst; 2016 Jun; 28(2):101-10. PubMed ID: 27133975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial.
    Pasquier D; Peiffert D; Nickers P; Maingon P; Pommier P; Lacornerie T; Martinage G; Tresch E; Lartigau E
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):116-123. PubMed ID: 31604131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simultaneous Integrated Boost Volumetric Modulated Arc Therapy in the Postoperative Treatment of High-Risk to Intermediate-Risk Endometrial Cancer: Results of ADA II Phase 1-2 Trial.
    Macchia G; Cilla S; Deodato F; Ianiro A; Legge F; Marucci M; Cammelli S; Perrone AM; De Iaco P; Gambacorta MA; Autorino R; Valentini V; Morganti AG; Ferrandina G
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):606-13. PubMed ID: 27681755
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
    Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
    Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.
    Boyer MJ; Papagikos MA; Kiteley R; Vujaskovic Z; Wu J; Lee WR
    Radiat Oncol; 2017 Jan; 12(1):14. PubMed ID: 28086825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
    Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter?
    Achard V; Jorcano S; Rouzaud M; Escudé L; Miralbell R; Zilli T
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1581-1588. PubMed ID: 30887155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.